Ryan Fields, MD

Surgeon

Primary Academic Title

Chief, Section of Surgical Oncology; Professor of Surgery, Division of General Surgery, Washington University School of Medicine

Clinical Expertise

As chief of the Section of Surgical Oncology and as a member of our sarcoma, pancreatic, liver, bile duct, stomach and skin cancer specialist teams, Dr. Fields is committed to providing patients with exceptional care.

Research Interest

The identification and treatment of patients at high risk for recurrence of their cancer and the use of novel treatment modalities to improve survival.

Education

2003: MD, Duke University, Durham, N.C.

Training

2003 - 2005: Resident, general surgery, Washington University, St. Louis
2005 - 2006: Research fellow, surgery and immunology, Washington University
2006 - 2009: Resident and chief resident, general surgery, Washington University
2009 - 2011: Fellow, surgical oncology, Memorial Sloan-Kettering Cancer Center, New York

Board Certification

2009: American Board of Surgery, General Surgery

Selected Research Publications

HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma.

Yamamoto N, Dobersch S, Loveless I, [...] Fields RC, [...] Kugel S
Clin Cancer Res 2025

Differential chromatin accessibility and transcriptional dynamics define breast cancer subtypes and their lineages.

Iglesia MD, Jayasinghe RG, Chen S, [...] Fields RC, [...] Ding L
Nat Cancer 2024

Tumour evolution and microenvironment interactions in 2D and 3D space.

Mo CK, Liu J, Chen S, [...] Fields RC, [...] Ding L
Nature 2024

Treatment resistance to melanoma therapeutics on a single cell level.

Yao L, Krasnick BA, Bi Y, [...] Fields RC
Sci Rep 2024

A Pan-Cancer Patient-Derived Xenograft Histology Image Repository with Genomic and Pathologic Annotations Enables Deep Learning Analysis.

White BS, Woo XY, Koc S, [...] Fields RC, [...] Chuang JH
Cancer Res 2024

Senescence Defines a Distinct Subset of Myofibroblasts That Orchestrates Immunosuppression in Pancreatic Cancer.

Belle JI, Sen D, Baer JM, [...] Fields RC, [...] DeNardo DG
Cancer Discov 2024

NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2024.

Swetter SM, Johnson D, Albertini MR, [...] Fields RC, [...] Espinosa S
J Natl Compr Canc Netw 2024

Senescence Defines a Distinct Subset of Myofibroblasts That Orchestrates Immunosuppression in Pancreatic Cancer.

Belle JI, Sen D, Baer JM, [...] Fields RC, [...] DeNardo DG
Cancer Discov 2024

Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer.

Bulle A, Liu P, Seehra K, [...] Fields RC, [...] Lim KH
Nat Commun 2024

Intratumoral T-cell receptor repertoire composition predicts overall survival in patients with pancreatic ductal adenocarcinoma.

Pothuri VS, Hogg GD, Conant L, [...] Fields RC
Oncoimmunology 2024

Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma.

Wu Y, Chen S, Yang X, [...] Fields RC, [...] Chen F
Cancer Res 2023

Area deprivation and rurality impact overall survival and adjuvant therapy administration in patients with pancreatic ductal adenocarcinoma (PDAC).

Pothuri V, Zárate Rodriguez JG, Kasting C, [...] Fields RC
HPB (Oxford) 2023

Epigenetic regulation during cancer transitions across 11 tumour types.

Terekhanova NV, Karpova A, Liang WW, [...] Fields RC, [...] Ding L
Nature 2023

High-dimensional deconstruction of pancreatic cancer identifies tumor microenvironmental and developmental stemness features that predict survival.

Storrs EP, Chati P, Usmani A, [...] Fields RC, [...] Chaudhuri AA
NPJ Precis Oncol 2023

Fibrosis induced by resident macrophages has divergent roles in pancreas inflammatory injury and PDAC.

Baer JM, Zuo C, Kang LI, [...] Fields RC, [...] DeNardo DG
Nat Immunol 2023

View All Publications